CoChat
Sign Up
Cited by 522Global Cancer Incidence and ScreeningProstate Cancer Diagnosis and TreatmentProstate Cancer Treatment and Research

The DOI matches its Crossref record; 26 of the 28 references it cites were found in a registry or an index.

Global Incidence and Mortality for Prostate Cancer: Analysis of Temporal Patterns and Trends in 36 Countries

Wong, Martin C.S., Goggins, William B., Wang, Harry H.X., Fung, Franklin D.H., Leung, Colette, Wong, Samuel Y.S., Ng, Chi Fai, Sung, Joseph J.Y.·2016·European Urology
DOI 10.1016/j.eururo.2016.05.043
Open this paper in CoChat — free account

Abstract

BACKGROUND: Prostate cancer (PCa) is a leading cause of mortality and morbidity globally, but its specific geographic patterns and temporal trends are under-researched. OBJECTIVE: To test the hypotheses that PCa incidence is higher and PCa mortality is lower in countries with higher socioeconomic development, and that temporal trends for PCa incidence have increased while mortality has decreased over time. DESIGN, SETTING, AND PARTICIPANTS: Data on age-standardized incidence and mortality rates in 2012 were retrieved from the GLOBOCAN database. Temporal patterns were assessed for 36 countries using data obtained from Cancer incidence in five continents volumes I-X and the World Health Organization mortality database. Correlations between incidence or mortality rates and socioeconomic indicators (human development index [HDI] and gross domestic product [GDP]) were evaluated. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: The average annual percent change in PCa incidence and mortality in the most recent 10 yr according to join-point regression. RESULTS AND LIMITATIONS: Reported PCa incidence rates varied more than 25-fold worldwide in 2012, with the highest incidence rates observed in Micronesia/Polynesia, the USA, and European countries. Mortality rates paralleled the incidence rates except for Africa, where PCa mortality rates were the highest. Countries with higher HDI (r=0.58) and per capita GDP (r=0.62) reported greater incidence rates. According to the most recent 10-yr temporal data available, most countries experienced increases in incidence, with sharp rises in incidence rates in Asia and Northern and Western Europe. A substantial reduction in mortality rates was reported in most countries, except in some Asian countries and Eastern Europe, where mortality increased. Data in regional registries could be underestimated. CONCLUSIONS: PCa incidence has increased while PCa mortality has decreased in most countries. The reported incidence was higher in countries with higher socioeconomic development. PATIENT SUMMARY: The incidence of prostate cancer has shown high variations geographically and over time, with smaller variations in mortality.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.eururo.2016.05.043

Cites

26 of 26 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Cited by

Sorted by citations

Items 401–500 of 522

Related

See all

Metadata

Authors
Wong, M. C. S., Goggins, W. B., Wang, H. H. X., Fung, F. D. H., Leung, C., Wong, S. Y. S., Ng, C. F., & Sung, J. J. Y.
Affiliations
  • Prince of Wales Hospital (CN)
  • Chinese University of Hong Kong (HK)
Corresponding author
Sung, Joseph J.Y.
ORCID
Venue
European Urology
Publisher
Elsevier BV
Published
2016-11
Volume
70
Issue
5
Pages
862-874
ISSN
0302-2838 (ISSN-L)
DOI
10.1016/j.eururo.2016.05.043
OpenAlex
W2415076046
Cited by
513
References
28
Citations by year
2026: 21 · 2025: 29 · 2024: 46 · 2023: 46 · 2022: 44 · 2021: 66 · 2020: 66 · 2019: 90 · 2018: 55 · 2017: 46 · 2016: 3
FWCI
34.88
Type
journal article
Language
en
Open access
closed
Licence
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations
  • European Urology (publishedVersion)
  • PubMed (publishedVersion)
  • ENLIGHTEN (Jurnal Bimbingan dan Konseling Islam) (acceptedVersion)
Topics
  • Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
  • Health Sciences › Medicine › Urology › Prostate Cancer Diagnosis and Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Prostate Cancer Treatment and Research
Keywords
prostate cancer, cancer incidence, cancer mortality, temporal trends, socio-economic development, Human Development Index, gross domestic product, global variation, age-standardized rates, cancer registry
MeSH terms
Adult, Age Factors, Aged, Developing Countries, Female, Humans, Male, Middle Aged, Mortality, Prostatic Neoplasms, Socioeconomic Factors, Global Health, World Health Organization, Incidence, Databases, Factual, Developed Countries

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review